Strides Arcolab Limited Inks Pact With Eli Lilly and Company for Cancer Drugs

US-based drug firm Eli Lilly and Co and domestic firm Strides ArcolabBSE -3.27 % today said they have entered into a pact to expand marketing of generic cancer medicines in the emerging markets. As a part of the arrangement, Eli Lilly will in-licence a portfolio of branded generic injectible and oral cancer medicines from Agila Specialties, the specialties division of Strides Arcolab, the companies said in a joint statement. Agila Specialties will manufacture the cancer medicines, and Lilly will register and market them in geographies across the emerging markets, it added. In addition to the initial 10 medicines included as part of the agreement, Lilly has the right to add additional high- quality branded generic oncology products to the portfolio in the future, the statement said. The two companies, however, did not disclose the financial details of the agreement. Commenting on the development, Lilly Senior Vice- President and President of its emerging markets division Jacques Tapiero said: "Building on our recent investment in a Lilly-branded generics platform in China earlier this year, this agreement will help Lilly expand its portfolio and deliver high-quality cancer medicines to patients across emerging markets".